Li-Min Wang
Research Subjects
Li-Min Wang has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Cheng Liao
Department of Preclinical Research and Development, Jiangsu Hengrui Pharmaceuticals Co. Ltd , Lianyungang, Jiangsu 222047
18 shared publications - Wei Zhang
Department of Preclinical Research and Development, Jiangsu Hengrui Pharmaceuticals Co. Ltd , Lianyungang, Jiangsu 222047
18 shared publications - Changyong Yang
Jiangsu Hengrui Pharmaceuticals Co. Ltd, Lianyungang, China
17 shared publications - Jiayi Li
State Key Laboratory of Microbial Metabolism Joint International Research Laboratory of Metabolic & Developmental Sciences School of Life Sciences & Biotechnology Shanghai Jiao Tong University Shanghai People's Republic of China
17 shared publications - Jieqiong Zhang
Jiangsu Hengrui Pharmaceuticals Co. Ltd, Lianyungang, China
17 shared publications - Lei Zhou
Shanghai Shengdi Pharmaceutical Co., Ltd., Shanghai, China
17 shared publications
Latest Publications
- Open Access
- 1 April 2026
- Published by Oxford University Press (OUP) in Antibody Therapeutics
- Vol. 9 (2) , 201-213
Development of SDP0505: a first-in-class HER3 × c-Met bispecific ADC, demonstrates potent antitumor activity in EGFR TKI-resistant NSCLC, CRC, and beyond
Background: Despite the success of third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC), acquired resistance remains an unmet need. Although human epidermal growth factor receptor 3 (HER3) and c-Met upregulation are key mechanisms of this resistance, the rationale for simultaneously targeting both to overcome this challenge remains unexplored. Methods: HER3 and c-Met expression were evaluated by immunohistochemistry in 270 clinical samples, including EGFR TKI-resistant NSCLC, lung adenocarcinoma (LUAD), gastric cancer, and colorectal cancer (CRC). The binding affinity of SDP0505 was measured by surface plasmon resonance and enzyme-linked immunosorbent assay, internalization was monitored using Incucyte, and in vitro cytotoxicity was assessed via CellTiter-Glo assay. The in vivo anti-tumor activities were investigated in cell-derived and patient-derived xenograft (PDX) models. Pharmacokinetics and repeated-dose toxicity were studied in cynomolgus monkeys. Results: Immunohistochemical analyses revealed spatial colocalization of HER3 and c-Met in EGFR TKI-resistant NSCLC specimens. Furthermore, high co-expression was observed in 58% of EGFR-mutant LUAD and 95% of CRC cases. Consequently, SDP0505 was developed with optimal antigen-binding affinity and antibody format through comprehensive screening. In HER3/c-Met dual-positive cell lines, SDP0505 demonstrated enhanced cell binding and internalization over the in-house synthesized U3-1402 analog. Superior in vivo antitumor efficacy was also observed in multiple NSCLC and CRC models, including EGFR TKI-resistant PDX models. Moreover, SDP0505 exhibited favorable pharmacokinetic and safety profiles in cynomolgus monkeys. Conclusions: SDP0505 represents a novel HER3 × c-Met ADC with superior internalization and anti-tumor activity in preclinical models, especially in EGFR TKI-resistant PDX models. These results supported the initiation of a Phase I clinical trial in China.
- 1 April 2026
- Published by Oxford University Press (OUP) in Antibody Therapeutics
- Vol. 9 (2) , 201-213
Open AccessDevelopment of SDP0505: a first-in-class HER3 × c-Met bispecific ADC, demonstrates potent antitumor activity in EGFR TKI-resistant NSCLC, CRC, and beyond
Background: Despite the success of third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC), acquired resistance remains an unmet need. Although human epidermal growth factor receptor 3 (HER3) and c-Met upregulation are key mechanisms of this resistance, the rationale for simultaneously targeting both to overcome this challenge remains unexplored. Methods: HER3 and c-Met expression were evaluated by immunohistochemistry in 270 clinical samples, including EGFR TKI-resistant NSCLC, lung adenocarcinoma (LUAD), gastric cancer, and colorectal cancer (CRC). The binding affinity of SDP0505 was measured by surface plasmon resonance and enzyme-linked immunosorbent assay, internalization was monitored using Incucyte, and in vitro cytotoxicity was assessed via CellTiter-Glo assay. The in vivo anti-tumor activities were investigated in cell-derived and patient-derived xenograft (PDX) models. Pharmacokinetics and repeated-dose toxicity were studied in cynomolgus monkeys. Results: Immunohistochemical analyses revealed spatial colocalization of HER3 and c-Met in EGFR TKI-resistant NSCLC specimens. Furthermore, high co-expression was observed in 58% of EGFR-mutant LUAD and 95% of CRC cases. Consequently, SDP0505 was developed with optimal antigen-binding affinity and antibody format through comprehensive screening. In HER3/c-Met dual-positive cell lines, SDP0505 demonstrated enhanced cell binding and internalization over the in-house synthesized U3-1402 analog. Superior in vivo antitumor efficacy was also observed in multiple NSCLC and CRC models, including EGFR TKI-resistant PDX models. Moreover, SDP0505 exhibited favorable pharmacokinetic and safety profiles in cynomolgus monkeys. Conclusions: SDP0505 represents a novel HER3 × c-Met ADC with superior internalization and anti-tumor activity in preclinical models, especially in EGFR TKI-resistant PDX models. These results supported the initiation of a Phase I clinical trial in China.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
CD40 expression in normal human and rhesus tissues by immunohistochemistry.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
CD40 expression in normal human and rhesus tissues by immunohistochemistry.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
The binding ability of 9E5 to TNF family members.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
The binding ability of 9E5 to TNF family members.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
The difference in the binding affinity of SHR-2005 to human and mouse FcgRIIb.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
The difference in the binding affinity of SHR-2005 to human and mouse FcgRIIb.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
Primary toxicokinetic parameters in rhesus after 4-week repeated administration of SHR-2005.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
Primary toxicokinetic parameters in rhesus after 4-week repeated administration of SHR-2005.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
Binding of SHR-2005 and APX005M analogue to CD40 from different species as determined by SPR assay.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
Binding of SHR-2005 and APX005M analogue to CD40 from different species as determined by SPR assay.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
The binding affinity of 9E5 to human FcgR as determined by SPR assay.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
The binding affinity of 9E5 to human FcgR as determined by SPR assay.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
The binding affinity and predicted binding mode of SHR-2005 to CD40.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
The binding affinity and predicted binding mode of SHR-2005 to CD40.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
Effects of SHR-2005 on the release of various cytokines in human peripheral blood mononuclear cells (PBMC).
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
Effects of SHR-2005 on the release of various cytokines in human peripheral blood mononuclear cells (PBMC).
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
Anti-tumor activity of SHR-2005-mIgG1 in vivo.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
Anti-tumor activity of SHR-2005-mIgG1 in vivo.